Evaluation of efficacy and safety of sorafenib in kidney cancer patients aged 75 years and older: a propensity score-matched analysis

BACKGROUND: The average age of patients diagnosed with renal cell carcinoma (RCC) is increasing, but a limited number of reports have described therapy of tyrosine kinase inhibitor for elderly RCC patients. Hence, we analysed the efficacy and safety of sorafenib in elderly patients aged ≥75 years wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Tatsugami, Katsunori, Oya, Mototsugu, Kabu, Koki, Akaza, Hideyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6048135/
https://www.ncbi.nlm.nih.gov/pubmed/29891937
http://dx.doi.org/10.1038/s41416-018-0129-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6048135/
https://www.ncbi.nlm.nih.gov/pubmed/29891937
http://dx.doi.org/10.1038/s41416-018-0129-3

Ejemplares similares